All Fresenius articles
-
NewsFDA warning letters highlight contamination control and facility maintenance failures
Findings from sterile drug manufacturing sites emphasise the agency’s expectation for companies to provide tangible evidence showing reduced quality and microbial risk and maintenance of control.
-
NewsEuropean decentralised CAR T manufacturing consortium launched
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.